

# Lourdes Calvo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1587637/publications.pdf>

Version: 2024-02-01

79  
papers

3,530  
citations

172207

29  
h-index

138251

58  
g-index

84  
all docs

84  
docs citations

84  
times ranked

4683  
citing authors

#	ARTICLE	IF	CITATIONS
1	Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study. <i>European Journal of Cancer</i> , 2022, 168, 12-24.	1.3	9
2	Combining Wire Localization of Clipped Nodes with Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer: Preliminary Results from a Prospective Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 958-967.	0.7	15
3	Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2-positive breast cancer?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 853-857.	1.4	9
4	Pembrolizumab plus eribulin in hormone-receptorâ€“positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase â€¦ trial. <i>European Journal of Cancer</i> , 2021, 148, 382-394.	1.3	22
5	Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptorâ€“positive metastatic breast cancer: Patient-reported outcomes in the PEARL study. <i>European Journal of Cancer</i> , 2021, 156, 70-82.	1.3	14
6	Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 827625.	1.3	7
7	Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). <i>Journal of Clinical Oncology</i> , 2020, 38, 203-213.	0.8	87
8	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 519-530.	5.1	441
9	Development and validation of a sexual relations satisfaction scale in patients with breast cancer â€” â€œSEXSAT-Qâ€” Health and Quality of Life Outcomes, 2019, 17, 143.	1.0	4
10	Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.6	11
11	Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study. <i>Clinical Breast Cancer</i> , 2019, 19, 105-112.	1.1	12
12	Hakai overexpression effectively induces tumour progression and metastasis in vivo. <i>Scientific Reports</i> , 2018, 8, 3466.	1.6	27
13	Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With <i>ERBB2/HER2</i>-Negative Breast Cancerâ€”The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial. <i>JAMA Oncology</i> , 2018, 4, 302.	3.4	115
14	Outcomes of single versus double hormone receptorâ€“positive breast cancer. A GEICAM/9906 sub-study. <i>European Journal of Cancer</i> , 2018, 94, 199-205.	1.3	21
15	Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution. <i>Breast Cancer: Targets and Therapy</i> , 2018, Volume 11, 29-42.	1.0	6
16	Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study. <i>Clinical and Translational Oncology</i> , 2017, 19, 91-104.	1.2	29
17	A PAM50-Based Chemoendocrine Score for Hormone Receptorâ€“Positive Breast Cancer with an Intermediate Risk of Relapse. <i>Clinical Cancer Research</i> , 2017, 23, 3035-3044.	3.2	28
18	Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention. <i>Clinical and Translational Oncology</i> , 2017, 19, 1067-1078.	1.2	11

#	ARTICLE	IF	CITATIONS
19	Physical activity and breast cancer risk by pathological subtype. <i>Gynecologic Oncology</i> , 2017, 144, 577-585.	0.6	34
20	Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis. <i>Oncologist</i> , 2017, 22, 1301-1308.	1.9	13
21	Proteomic Analysis of the E3 Ubiquitin-Ligase Hakai Highlights a Role in Plasticity of the Cytoskeleton Dynamics and in the Proteasome System. <i>Journal of Proteome Research</i> , 2017, 16, 2773-2788.	1.8	9
22	A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM). <i>Clinical and Translational Oncology</i> , 2017, 19, 616-624.	1.2	3
23	Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM "El Álamo III" retrospective study. <i>PLoS ONE</i> , 2017, 12, e0184181.	1.1	0
24	Diagnostic accuracy of MRI to evaluate tumour response and residual tumour size after neoadjuvant chemotherapy in breast cancer patients. <i>Radiology and Oncology</i> , 2016, 50, 73-79.	0.6	35
25	High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer. <i>Oncologist</i> , 2016, 21, 150-155.	1.9	35
26	Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study. <i>European Journal of Cancer</i> , 2016, 58, 122-129.	1.3	8
27	Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 81-89.	1.1	38
28	ETNA (Evaluating Treatment with Neoadjuvant Abraxane) randomized phase III study comparing neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) both followed by anthracycline regimens in women with HER2-negative high-risk breast cancer: A MICHELANGO study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 502-502.	0.8	9
29	Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile. <i>Current Cancer Drug Targets</i> , 2016, 16, 415-428.	0.8	10
30	Outcomes of single versus double hormone receptor positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 569-569.	0.8	1
31	Circulating miR-200c and miR-141 and outcomes in patients with breast cancer. <i>BMC Cancer</i> , 2015, 15, 297.	1.1	72
32	Clinical implications of epithelial cell plasticity in cancer progression. <i>Cancer Letters</i> , 2015, 366, 1-10.	3.2	43
33	Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression. <i>Oncologist</i> , 2015, 20, 474-482.	1.9	145
34	Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3788-3795.	0.8	56
35	Standard Versus Continuous Administration of Capecitabine in Metastatic Breast Cancer (GEICAM/2009-05): A Randomized, Noninferiority Phase II Trial With a Pharmacogenetic Analysis. <i>Oncologist</i> , 2015, 20, 111-112.	1.9	20
36	Abstract OT1-1-06: A phase I study of LDE225 in combination with docetaxel in patients with triple negative (TN) advanced breast cancer (ABC): GEICAM/2012-12 (EDALINE study). , 2015, , .		1

#	ARTICLE	IF	CITATIONS
37	Abstract P2-13-17: Impact on survival of primary tumor resection in women with de novo metastatic breast cancer. The GEICAM Alamo III breast cancer registry (1990-2001)., 2015, , .		0
38	Abstract OT2-2-03: MERIBEL study: Efficacy of eribulin in first line of taxane-resistant patients with HER2 negative metastatic breast cancer. , 2015, , .		0
39	Circulating levels of GDF15, MMP7 and miR-200c as a poor prognostic signature in gastric cancer. Future Oncology, 2014, 10, 1187-1202.	1.1	37
40	Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2 <sup>+</sup> breast cancer patients: results from the GEICAM 9906 trial. Breast Cancer Research, 2014, 16, R38.	2.2	133
41	Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial. British Journal of Cancer, 2014, 110, 1139-1147.	2.9	58
42	Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: Results from a 2-year multicentre observational study (ZOMAR study). Bone, 2014, 68, 32-40.	1.4	18
43	Predicting response and survival in chemotherapy-treated triple-negative breast cancer. British Journal of Cancer, 2014, 111, 1532-1541.	2.9	100
44	Breast cancer management in the elderly. Clinical and Translational Oncology, 2014, 16, 351-361.	1.2	5
45	Nabrax: Neoadjuvant therapy of breast cancer with weekly single-agent nab-paclitaxel <sup>®</sup> Final efficacy and biomarkers analysis of GEICAM 2011-02 trial.. Journal of Clinical Oncology, 2014, 32, 1051-1051.	0.8	3
46	Subtype analysis from the GEICAM/2003-02 study: High-risk, node-negative breast cancer patients treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel.. Journal of Clinical Oncology, 2014, 32, 11107-11107.	0.8	1
47	Triple-negative breast cancer subtypes and pathologic complete-response rate to neoadjuvant chemotherapy: Results from the GEICAM/2006-2003 study.. Journal of Clinical Oncology, 2014, 32, 1024-1024.	0.8	1
48	Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study. Journal of Clinical Oncology, 2013, 31, 2593-2599.	0.8	52
49	Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. Breast Cancer Research, 2013, 15, R105.	2.2	80
50	Circulating MicroRNAs: Molecular Microsensors in Gastrointestinal Cancer. Sensors, 2012, 12, 9349-9362.	2.1	31
51	A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Research and Treatment, 2012, 136, 487-493.	1.1	127
52	Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. Journal of Translational Medicine, 2012, 10, 186.	1.8	130
53	Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Annals of Oncology, 2012, 23, 3069-3074.	0.6	158
54	Phase I/II study of biweekly vinorelbine and oxaliplatin as first-line treatment in patients with metastatic breast cancer. Anti-Cancer Drugs, 2011, 22, 283-289.	0.7	4

#	ARTICLE	IF	CITATIONS
55	Prognostic impact of disseminated tumor cells and microRNA-17-92 cluster deregulation in gastrointestinal cancer. <i>International Journal of Oncology</i> , 2011, 39, 1253-64.	1.4	35
56	Regional and seasonal influence in patient's toxicity to adjuvant chemotherapy for early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 273-278.	1.1	5
57	A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study. <i>Clinical and Translational Oncology</i> , 2011, 13, 686-691.	1.2	3
58	Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study. <i>Annals of Oncology</i> , 2011, 22, 74-79.	0.6	30
59	Current controversies in the management of breast cancer. <i>Clinical and Translational Oncology</i> , 2010, 12, 278-286.	1.2	2
60	Locally advanced breast cancer: pulmonary toxicity secondary to gemcitabine. <i>Clinical and Translational Oncology</i> , 2010, 12, 450-452.	1.2	3
61	SEOM clinical guidelines for the treatment of metastatic breast cancer. <i>Clinical and Translational Oncology</i> , 2010, 12, 719-723.	1.2	6
62	Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 149-157.	1.1	77
63	Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2010, 363, 2200-2210.	13.9	169
64	Novel therapeutic approaches to the treatment of metastatic breast cancer. <i>Cancer Treatment Reviews</i> , 2010, 36, 33-42.	3.4	52
65	Diagnostic accuracy of small breast epithelial mucin mRNA as a marker for bone marrow micrometastasis in breast cancer: a pilot study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 1185-1195.	1.2	18
66	Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 351-358.	1.1	10
67	Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study. <i>Annals of Oncology</i> , 2009, 20, 454-459.	0.6	13
68	Phase II study of dose-dense doxorubicin and docetaxel as neoadjuvant chemotherapy with G-CSF support in patients with large or locally advanced breast cancer. <i>Clinical and Translational Oncology</i> , 2008, 10, 739-744.	1.2	2
69	Time-to-progression in breast cancer: A stratification model for clinical trials. <i>Breast</i> , 2008, 17, 239-244.	0.9	2
70	A Single-Nucleotide Polymorphism in the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor Letrozole in Advanced Breast Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 811-816.	3.2	113
71	Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2008, 100, 805-814.	3.0	208
72	Neoadjuvant endocrine therapy for breast cancer: past, present and future. <i>Anti-Cancer Drugs</i> , 2008, 19, 339-347.	0.7	14

#	ARTICLE	IF	CITATIONS
73	Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. <i>Lancet Oncology</i> , The, 2007, 8, 219-225.	5.1	181
74	Subacute Cerebellar Degeneration as Paraneoplastic Syndrome: Initial Symptom of Breast Cancer with HER2 Overexpression. <i>Clinical Breast Cancer</i> , 2006, 7, 79-80.	1.1	11
75	Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. <i>Annals of Oncology</i> , 2006, 17, 1205-1212.	0.6	171
76	Evaluation of Messenger RNA of Pituitary Tumour-transforming Gene-1 (PTTG1) as a Molecular Marker for Micrometastasis. , 2005, , 462-467.		0
77	Docetaxel/Gemcitabine Administered Every Other Week as First-Line Treatment for Metastatic Breast Cancer: Final Results of a Phase II Trial. <i>Clinical Breast Cancer</i> , 2005, 6, 433-438.	1.1	21
78	Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer: Preliminary results from a phase II trial. <i>Seminars in Oncology</i> , 2004, 31, 20-24.	0.8	13
79	A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex®) with intramuscular formestane in postmenopausal women with advanced breast cancer. <i>Annals of Oncology</i> , 1999, 10, 1219-1225.	0.6	16